網頁

Thursday, June 16, 2022

BIO 宣佈新一屆執委

 BIO Elects New Board Directors and

Re-Elects Section Governing Board Chairs

 

San Diego, Calif. (June 15, 2022) – The Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Executive Committee directors for the 2022-2023 term.

 

BIO’s Board elections took place Monday, June 13 during the 2022 BIO International Convention hosted by BIO in San Diego, June 13-16, 2022.

 

“On behalf of our entire BIO organization, I want to congratulate our incoming Board directors and section leaders,” said Dr. Michelle McMurry-Heath, President & CEO of BIO. “This is a critical time for our industry. Our BIO Board – especially one as diverse and multi-faceted as this one – will help drive policies that keeps pace with innovation’s promise to cure disease, nourish society, and protect our planet.”

 

BIO’s Executive Committee directors for the 2022-2023 term are:

§  Paul Hastings, Nkarta Therapeutics – Board Chair/Health Section Chair

§  Elizabeth Lewis, Takeda Pharmaceuticals – Board Associate Vice Chair & Secretary

§  Bradford Zakes, Ceravast Medical – BIO Board Treasurer

§  Ted Love, Global Blood Therapeutics – Health Section Vice Chair

§  Sylvia Wulf, AquaBounty Technologies – Agriculture & Environment Section Chair

§  John Crowley, Amicus Therapeutics – Emerging Companies Section Chair

§  Jeremy Levin, Ovid Therapeutics – Immediate Past Chair

§  Erika Smith, ReNetX BIO – Emerging Companies Section Vice Chair

§  Anna Rath, Vestaron

§  Doug Doerfler, MaxCyte

§  Stuart Arbuckle, Vertex Pharmaceuticals

§  Christi Shaw, Kite, A Gilead Company

§  Bill Sibold, Genzyme, A Sanofi Company

§  Fritz Bittenbender, Genentech Roche

§  Chris Boerner, Bristol Myers Squibb

§  Eric Dube, Travere Therapeutics

§  Sue Washer, Applied Genetic Technologies Corporation (AGTC)

§  Aamir Malik, Pfizer

§  Jannie Oosthuizen, Merck

§  Victor Bulto, Novartis Pharmaceuticals

§  Bill Newell, Sutro BioPharma

 

Additional directors who were confirmed as the Executive Advisory Board (EAB) to the Executive Committee:

§  Ron Cohen, Acorda Therapeutics

§  Rachel King, former BIO Board Chair

§  John Maraganore, former BIO Board Chair

§  Richard Pops, Alkermes

 

Newly Elected to the BIO Health Section Governing Board (2022-2025 Term):

§  Jannie Oosthuizen, Merck

 

Newly Elected to the BIO Emerging Companies Section Governing Board (2022-2023 Term):

§  Pablo Cagnoni, Rubius Therapeutics

§  Kaye Foster, The Boston Consulting Group

§  Mike Huckman, Real Chemistry

§  Elizabeth Jeffords, Iolyx Therapeutics

§  Sheila Mikhail, Asklepios BioPharmaceutical

 

Newly Elected to the BIO Agriculture and Environment Section Governing Board (2022-2024 Term):

§  Angela Ailloni, Ginkgo Bioworks

§  Rocco Morelli, Recombinetics

No comments:

Post a Comment